Literature DB >> 1710267

Phenotypic heterogeneity in the syndromes of 3-methylglutaconic aciduria.

K M Gibson1, W G Sherwood, G F Hoffman, D A Stumpf, I Dianzani, R B Schutgens, P G Barth, U Weismann, C Bachmann, P Schrynemackers-Pitance.   

Abstract

Combined 3-methylglutaconic and 3-methylglutaric aciduria, one of the more common urinary organic acid abnormalities, has been observed in at least three clinical syndromes. We studied an additional seven patients with 3-methylglutaconic aciduria, four of whom were best categorized as having the type II syndrome, two as having an "unspecified" syndrome, and one who may have had a primary urea cycle defect. In cultured cells and autopsy tissues derived from patients with the type II and unspecified syndromes, we were unsuccessful in identifying a defect in the leucine degradative pathway distal to 3-methylcrotonyl-coenzyme A carboxylase and in the cholesterol biosynthetic pathway between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and diphosphomevalonate decarboxylase. Further assessment of the cholesterol biosynthetic pathway in several patients with one of the two types of disease also provided no defined abnormality. The primary metabolic defects in the type II and unspecified syndromes remain undefined.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710267     DOI: 10.1016/s0022-3476(05)82199-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  3-Methylglutaconic aciduria type I: clinical heterogeneity as a neurometabolic disease.

Authors:  Y Shoji; T Takahashi; Y Sawaishi; A Ishida; M Matsumori; Y Shoji; M Enoki; H Watanabe; G Takada
Journal:  J Inherit Metab Dis       Date:  1999-02       Impact factor: 4.982

2.  3-Methylglutaconyl-CoA hydratase deficiency: a new patient with speech retardation as the leading sign.

Authors:  R Ensenauer; C B Müller; K O Schwab; K M Gibson; M Brandis; W Lehnert
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

3.  3-Methylglutaconic aciduria: a marker for as yet unspecified disorders and the relevance of prenatal diagnosis in a 'new' type ('type 4').

Authors:  D Chitayat; J Chemke; K M Gibson; O A Mamer; J B Kronick; J J McGill; B Rosenblatt; L Sweetman; C R Scriver
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

4.  3-Methylglutaconic aciduria in a patient with a disturbed mitochondrial energy metabolism.

Authors:  J A Bakkeren; R C Sengers; W Ruitenbeek; J M Trijbels
Journal:  Eur J Pediatr       Date:  1992-04       Impact factor: 3.183

5.  Mutation characterization and genotype-phenotype correlation in Barth syndrome.

Authors:  J Johnston; R I Kelley; A Feigenbaum; G F Cox; G S Iyer; V L Funanage; R Proujansky
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

6.  Multiple respiratory chain abnormalities associated with hypertrophic cardiomyopathy and 3-methylglutaconic aciduria.

Authors:  H Ibel; W Endres; H B Hadorn; T Deufel; I Paetzke; M Duran; N G Kennaway; K M Gibson
Journal:  Eur J Pediatr       Date:  1993-08       Impact factor: 3.183

Review 7.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

8.  Mitochondrial complex deficiencies in a male with cardiomyopathy and 3-methylglutaconic aciduria.

Authors:  G T Besley; M Lendon; D M Broadhead; J Till; L E Heptinstall; B Phillips
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

9.  3-Methylglutaconic aciduria in a patient with Pearson syndrome.

Authors:  U Lichter-Konecki; F K Trefz; A Rötig; A Munnich; A Pfeil; H J Bremer
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

10.  Dilated cardiomyopathy with 3-methylglutaconic aciduria.

Authors:  J M Draaisma; I C van Kesteren; O Daniëls; R C Sengers
Journal:  Pediatr Cardiol       Date:  1994 Mar-Apr       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.